DEVOURED
A DeepSeek Moment for Biotech
Chinese pharmaceutical firms are managing a third of the global drug pipeline but remain largely dependent on Western partnerships for international market entry.
What: Despite a massive volume of clinical trials in China, companies like Akeso rely on licensing deals with Western entities to navigate late-stage development and commercialization abroad.
Original article
Chinese drugmakers account for at least a third of the world's pipeline of innovative drugs in development, but China-originated novel treatments have yet to reach overseas markets at scale. The country runs more clinical trials than any place else. Chinese drugmakers with global ambitions currently pursue them primarily through partnerships with Western companies, who usually take charge of late-stage development and eventual sales of the drugs outside of China. Some lawmakers in the US are calling for restrictions on partnerships with Chinese companies, but industry analysts say the business momentum is too strong to break.
Explore all 57 articles in today's digest
Fresh dev news, AI-digested daily. Never miss a trend at devoured.fyi